Phase 2Terminated
Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection
- Sponsor
- Arrevus Inc. (Industry)
- Enrollment
- 14 enrolled
- Conditions
- Prosthetic Joint Infections of Hip; Prosthetic Joint Infections of Knee; Infected Spacers
- Interventions
- CEM-102; IV or Oral standard of care antibiotics; Rifampin
- Ages
- adults, older adults
- Registry
- NCT01756924
Full record on ClinicalTrials.gov
From the registry
To determine if oral antibiotic treatment with CEM-102 and Rifampin is as effective and safe as the standard of care antibiotic therapy for the treatment of hip and knee prosthetic joint or spacer infections
Primary outcomes
- Bacterial eradication of joint infection
History
Last registry update
Primary completion
Registered
Started